CS27109, A Selective Thyroid Hormone Receptor-β Agonist Alleviates Metabolic-Associated Fatty Liver Disease in Murine Models

Figure 1

Schematic representation of in vivo studies: (a) experimental procedure of developing a hamster model with HFD + CHOL and testing drug efficacy, (b) experimental procedure of developing an SD rat model with HFD and testing drug efficacy, and (c) experimental procedure of developing a mouse model with WD + CCL4 and testing drug efficacy.

(a)

(b)

(c)